- This event has passed.
Breakfast Briefing: Biosimilars and Protecting R&D Dollars
June 2, 2011 @ 7:30 am - 10:30 amVaries
Thank you for joining us at
BioNJ’s Breakfast Briefing:
Biosimilars and Protecting R&D Dollars
June 2, 2011
BioNJ held their latest Breakfast Briefing on Thursday, June 2, 2011 at the Bridgewater Manor as the region’s leading experts discussed Biosimilars and Protecting R&D Dollars.
Please CLICK HERE for a press release about the event.
Slide Presentations Available for Download
The Potential Economic Impact of Biosimilars in the US Market — Joseph Fuhr, Jr., Ph.D.
The Payment System Impact on Biosimilars Adoption — James Langley
EU Biosimilarity Guidance — Shefali Kakar, Ph.D.
Introduction of landmark legislation has changed the biotechnology marketplace, allowing for biosimilar products to be marketed in the U.S. Biotechnology companies will have to defend prime marketplace real estate, protect the rewards granted by innovative R&D and potentially compete on price. Historically, however, biosimilars have not generated much traction as evidenced by somatropin or epogen in Europe. Is this an anomaly or are we facing a new reality? This session invites the panel to discuss the challenges, lessons and opportunities associated with biosimilars in the U.S.
Nick Colucci, CEO and President, Publicis Healthcare Communications Group
Joseph Fuhr, Jr., Ph.D., ACI Senior Fellow and Professor of Economics at Widener University
Michael Castagna, Pharm.D., Executive Director, Orencia, Bristol-Myers Squibb; Former Vice President, Sales and Marketing Biopharmaceuticals, Sandoz Inc.
Shefali Kakar Ph.D., Senior Fellow, Oncology Pharmacology, Novartis Pharmaceuticals Corporation
Gillian Cannon, Vice President, BioVentures, Merck
James Langley, Former Senior Vice President of Reimbursement, Accredo Health Group